DFD-29 Achieves Coprimary and Secondary End Points for Papulopustular Rosacea

Anew treatment for moderate to severe papulopustular rosacea in adults may soon be on the horizon, as Journey Medical Corporation recently announced the positive topline data from its 2 phase 3 clinical trials investigating DFD-29.1 The multicenter, randomized, double-blind, parallel-group, active-c...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology Times 2023-08, Vol.44 (8), p.20-20
Main Author: Bader, Kaitlyn
Format: Article
Language:English
Subjects:
Clinical trials
Dermatology
Success
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anew treatment for moderate to severe papulopustular rosacea in adults may soon be on the horizon, as Journey Medical Corporation recently announced the positive topline data from its 2 phase 3 clinical trials investigating DFD-29.1 The multicenter, randomized, double-blind, parallel-group, active-comparator, and placebo-controlled clinical trials, MVOR-1 (NCT05296629) and MVOR-2 (NCT05343455), are evaluating 40-mg minocycline hydrochloride modified-release capsules, known as DFD-29. In both trials (n = 640), DFD-29 demonstrated superiority over both doxycycline (Oracea) capsules and placebo for Investigator's Global Assessment (IGA) treatment success and in the reduction in the total inflammatory lesion count. The proportion of patients achieving IGA treatment success in the DFD-29 group was superior to those in the doxycycline and placebo groups.
ISSN:0196-6197
2150-6523